High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naïve metastatic prostate cancer -Results from a prospective pilot study using a 37 gene panel.

•Pilot study that demonstrates the feasibility, performance and clinical relevance of somatic targeted NGS using a novel 37 DNA damage repair and checkpoint gene panel under routine conditions.•Detection of actionable DNA repair gene alterations, uncommon mutations as well as mutations associated with therapy resistance in a high number of patients.•High prevalence of DNA damage repair and checkpoint gene perturbations in particular in patients with treatment-naïve metastatic prostate cancer.